MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.32−0.14 (-1.65%)
Close on Nov 18, 2026Market cap $799.08MP/E 11.7Yield –
MeiraGTx operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
MeiraGTx's operating cash flow for the twelve months ending Jun 30, 2026 was $13.69M. For fiscal 2025 it was -$46.36M. The highest annual figure on record is $20.04M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$46.36M | – |
| FY2024 | Dec 31, 2024 | -$104.50M | – |
| FY2023 | Dec 31, 2023 | -$105.37M | – |
| FY2022 | Dec 31, 2022 | -$73.10M | – |
| FY2021 | Dec 31, 2021 | -$10.53M | – |
| FY2020 | Dec 31, 2020 | -$63.97M | -419.1% |
| FY2019 | Dec 31, 2019 | $20.04M | – |
| FY2018 | Dec 31, 2018 | -$58.89M | – |
| FY2017 | Dec 31, 2017 | -$18.06M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$38.54M | – |
| Q1 FY2026 | Mar 31, 2026 | $17.81M | – |
| Q4 FY2025 | Dec 31, 2025 | $46.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.22M | – |
| Q2 FY2025 | Jun 30, 2025 | -$43.95M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.83M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.46M | – |
| Q1 FY2024 | Mar 31, 2024 | -$36.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$29.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$37.39M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.27M | -186.4% |
| Q3 FY2022 | Sep 30, 2022 | -$20.73M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.30M | -191.3% |
| Q4 FY2021 | Dec 31, 2021 | $18.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.18M | – |
| Q2 FY2021 | Jun 30, 2021 | -$21.26M | – |
| Q1 FY2021 | Mar 31, 2021 | $9.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$29.56M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.14M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.88M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.38M | -115.1% |
| Q4 FY2019 | Dec 31, 2019 | -$21.97M | – |
| Q3 FY2019 | Sep 30, 2019 | -$18.41M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.74M | – |
| Q1 FY2019 | Mar 31, 2019 | $82.17M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.47M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.99M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.03M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.40M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.71M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.82M | – |
See a number that looks wrong?